Cargando…

Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor

(1) Background: Two first-in-class racemic dopamine D(1) receptor (D(1)R) positive allosteric modulator (PAM) chemotypes (1 and 2) were identified from a high-throughput screen. In particular, due to its selectivity for the D(1)R and reported lack of intrinsic activity, compound 2 shows promise as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fyfe, Tim J., Scammells, Peter J., Lane, J. Robert, Capuano, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270344/
https://www.ncbi.nlm.nih.gov/pubmed/34206465
http://dx.doi.org/10.3390/molecules26133799
_version_ 1783720785101193216
author Fyfe, Tim J.
Scammells, Peter J.
Lane, J. Robert
Capuano, Ben
author_facet Fyfe, Tim J.
Scammells, Peter J.
Lane, J. Robert
Capuano, Ben
author_sort Fyfe, Tim J.
collection PubMed
description (1) Background: Two first-in-class racemic dopamine D(1) receptor (D(1)R) positive allosteric modulator (PAM) chemotypes (1 and 2) were identified from a high-throughput screen. In particular, due to its selectivity for the D(1)R and reported lack of intrinsic activity, compound 2 shows promise as a starting point toward the development of small molecule allosteric modulators to ameliorate the cognitive deficits associated with some neuropsychiatric disease states; (2) Methods: Herein, we describe the enantioenrichment of optical isomers of 2 using chiral auxiliaries derived from (R)- and (S)-3-hydroxy-4,4-dimethyldihydrofuran-2(3H)-one (d- and l-pantolactone, respectively); (3) Results: We confirm both the racemate and enantiomers of 2 are active and selective for the D(1)R, but that the respective stereoisomers show a significant difference in their affinity and magnitude of positive allosteric cooperativity with dopamine; (4) Conclusions: These data warrant further investigation of asymmetric syntheses of optically pure analogues of 2 for the development of D(1)R PAMs with superior allosteric properties.
format Online
Article
Text
id pubmed-8270344
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82703442021-07-10 Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor Fyfe, Tim J. Scammells, Peter J. Lane, J. Robert Capuano, Ben Molecules Article (1) Background: Two first-in-class racemic dopamine D(1) receptor (D(1)R) positive allosteric modulator (PAM) chemotypes (1 and 2) were identified from a high-throughput screen. In particular, due to its selectivity for the D(1)R and reported lack of intrinsic activity, compound 2 shows promise as a starting point toward the development of small molecule allosteric modulators to ameliorate the cognitive deficits associated with some neuropsychiatric disease states; (2) Methods: Herein, we describe the enantioenrichment of optical isomers of 2 using chiral auxiliaries derived from (R)- and (S)-3-hydroxy-4,4-dimethyldihydrofuran-2(3H)-one (d- and l-pantolactone, respectively); (3) Results: We confirm both the racemate and enantiomers of 2 are active and selective for the D(1)R, but that the respective stereoisomers show a significant difference in their affinity and magnitude of positive allosteric cooperativity with dopamine; (4) Conclusions: These data warrant further investigation of asymmetric syntheses of optically pure analogues of 2 for the development of D(1)R PAMs with superior allosteric properties. MDPI 2021-06-22 /pmc/articles/PMC8270344/ /pubmed/34206465 http://dx.doi.org/10.3390/molecules26133799 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fyfe, Tim J.
Scammells, Peter J.
Lane, J. Robert
Capuano, Ben
Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor
title Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor
title_full Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor
title_fullStr Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor
title_full_unstemmed Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor
title_short Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor
title_sort enantioenriched positive allosteric modulators display distinct pharmacology at the dopamine d(1) receptor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270344/
https://www.ncbi.nlm.nih.gov/pubmed/34206465
http://dx.doi.org/10.3390/molecules26133799
work_keys_str_mv AT fyfetimj enantioenrichedpositiveallostericmodulatorsdisplaydistinctpharmacologyatthedopamined1receptor
AT scammellspeterj enantioenrichedpositiveallostericmodulatorsdisplaydistinctpharmacologyatthedopamined1receptor
AT lanejrobert enantioenrichedpositiveallostericmodulatorsdisplaydistinctpharmacologyatthedopamined1receptor
AT capuanoben enantioenrichedpositiveallostericmodulatorsdisplaydistinctpharmacologyatthedopamined1receptor